Molecular Mechanisms of Collagen Isotype-Specific Modulation of Smooth Muscle Cell Phenotype

A. Wayne Orr, Monica Y. Lee, Julia A. Lemmon, Arif Yurdagul Jr, Maria F. Gomez, Pamela D. Schoppee Bortz, Brian R. Wamhoff

Objective—Smooth muscle cell (SMC) phenotypic modulation, an important component of atherosclerosis progression, is critically regulated by the matrix, with normal components of the healthy SMC matrix limiting modulation and atherosclerosis-associated transitional matrix proteins promoting phenotypic modulation. We sought to determine how collagen IV (which comprises the healthy artery wall) and monomeric collagen I (which comprises atherosclerotic lesions) differentially affect SMC phenotype.

Methods and Results—Plating SMCs on collagen IV resulted in elevated expression of SMC contractility proteins compared to collagen I. Concurrent with enhanced contractile gene expression, collagen IV stimulates binding of SRF to CArG boxes in the promotors of smooth muscle actin and smooth muscle myosin heavy chain. Coll IV also stimulated the expression of myocardin, a critical SRF coactivator required to drive expression of SMC specific genes. In contrast to collagen IV, collagen I stimulated enhanced expression of the inflammatory protein vascular cell adhesion molecule (VCAM)-1. NF-κB and NFAT-binding sites in the VCAM-1 promoter are critical for collagen I–mediated expression of VCAM-1 promoter activity. However, only inhibitors of NFAT, not NF-κB, were able to reduce collagen I–associated VCAM expression, and collagen I but not collagen IV stimulated NFAT transcriptional activity.

Conclusion—These results show for the first time that collagen IV and collagen I differentially affect smooth muscle phenotypic modulation through multiple pathways. (Arterioscler Thromb Vasc Biol. 2009;29:225-231.)

Key Words: transcription ■ differentiation ■ inflammation ■ NFAT ■ matrix

Cardiovascular disease is the leading cause of death in developed countries and is showing increasing incidence in the developing world. More than 80% of the cardiovascular disease–associated mortality is attributable to atherosclerosis, a chronic inflammatory disease of the vessel wall. At early stages, atherogenesis is driven by endothelial cell dysfunction and monocyte recruitment, while at late stages progression is generated by smooth muscle cell (SMC) proliferation, migration, and fibrosis. SMCs regulate vascular tone through alterations in their contractile properties and as such express a unique subset of contractility-related genes, including SM α-actin (SMA), smooth muscle myosin heavy chain (SM-MHC), smoothelin, calponin, and desmin. SMC activation during atherosclerotic progression induces the loss of this “contractile phenotype” and the adoption of a “synthetic phenotype,” characterized by enhanced proliferation, migration, and expression of fibrotic and inflammatory proteins concomitant with decreased expression of contractility-associated proteins. This change, termed phenotypic modulation, is thought to play a critical role in the progression of atherosclerosis from a clinically silent fatty streak into an advanced atheroma, and stimulating SMCs to transition back to a contractile phenotype may induce plaque stabilization.

While the function of cell cycle regulators and profibrotic genes in atherosclerotic progression are well described, the role of inflammatory gene expression in SMCs has puzzled scientists for more than a decade. The extracellular matrix regulates both tissue architecture and cell phenotype. Cells use matrix receptors, such as integrins, to detect the changes in matrix rigidity and composition that occur during tissue remodeling. The resulting intracellular signals regulate a number of cellular processes including cell proliferation, survival, differentiation, and gene expression. SMCs are normally surrounded by a basal laminae, but in regions of early atherosclerosis this matrix is degraded allowing SMC interactions with the interstitial matrix. Basal laminae proteins such as collagen IV (Coll IV), laminin, and perlecan can limit SMC growth, enhance contractile gene expression, reduce inflammatory gene expression, reduce LDL uptake in culture, and inhibit matrix...
Calcification. In contrast, the interstitial matrix proteins, including collagen I (Coll I), collagen III, fibronectin, and osteopontin, enhance SMC growth concomitant with elevated extracellular signal regulated kinase (ERK) phosphorylation and expression of cell cycle regulators. Inhibiting the integrins that bind these interstitial matrix proteins is sufficient to block SMC proliferation in response to PDGF, EGF, and bFGF and to reduce migration and neointima formation in vivo. Whereas Coll IV and polymerized Coll I limit SMC growth and promote the contractile phenotype, monomeric Coll I reduces contractile gene expression. Monomeric Coll I may be relevant to atherosclerotic plaques, because enhanced Coll I degradation in the atherosclerotic plaque is thought to promote the release of monomeric Coll I. Despite 30 years of research in the area, the molecular mechanisms by which the matrix alters SMC gene expression in phenotypic modulation are unknown.

Smooth muscle–specific contractile gene promoters are active under physiological conditions but are terminally silenced in response to injury or atherosclerosis. Nearly all gene promoters for smooth muscle-specific contractile proteins contain at least 2 CArG cis regulatory elements. CArG boxes bind SRF (serum response factor), which requires myocardin or myocardin-related transcription factors (MRTFs). Many growth factors and cytokines implicated in SMC phenotypic modulation have been shown to regulate this process, including platelet-derived growth factor (PDGF), angiotensin-II, transforming growth factor beta (TGF-β), and recently oxidized phospholipids and sphingosine-1-phosphate. However, regulation by the extracellular matrix has not been addressed.

The current work examines the molecular mechanisms by which a “protective” matrix (Coll IV) or an “atherosclerotic” matrix (monomeric collagen I) differentially affect SMC gene expression. We now show that the extracellular matrix alters SMC-specific contractile gene expression through differential effects on SRF recruitment to CArG boxes in the promoters of SMA and SM-MHC and through differential regulation of myocardin expression. We also demonstrate for the first time that Coll IV promotes the expression of the inflammatory protein VCAM-1, and we show that this induction is NFAT-dependent.

Methods

The current study uses rat aortic SMCs plated under serum-free conditions on either Coll I (20 μg/mL; Sigma) or Coll IV (20 μg/mL; Chemicon and Trevigen). Promoter-luciferase reporter constructs for SMA, SM-MHC, VCAM-1, and NFATc (Clonetech) were transfected using FuGENE6 (Roche) and used to measure promoter activity. Total mRNA was extracted using Trizol (Invitrogen), cDNA was synthesized using the iScript cDNA synthesis kit (BioRad), and quantitative real-time polymerase chain reaction (PCR) was used to measure SMA, SM-MHC, myocardin, and VCAM-1 mRNA expression as previously described.

Western blotting was used to measure protein expression. Chromatin immunoprecipitation (ChIP) was used to measure SRF enrichment on the SMA and SM-MHC promoters as previously described. Please see the supplemental materials for expanded Materials and Methods section (available online at http://atvb.ahajournals.org).
and in the intronic CArG box. Mutation of any of the CArG boxes reduced the enhanced promoter activity in cells plated on Coll IV (Figure 2C), suggesting that Coll IV enhances the expression of smooth muscle contractile genes by promoting the recruitment of SRF to the CArG boxes present in the promoters of the target genes. We then tested whether the SRF coactivator myocardin showed differential expression in response to different Coll matrices. Quantitative RT-PCR revealed that plating cells on Coll IV induced a significant increase in myocardin mRNA expression compared to cells on Coll I (Figure 2D), suggesting differential regulation of myocardin expression is an underlying cause of matrix-specific phenotypic modulation. SRF protein expression was not altered by Coll IV compared to Coll I (Figure 2E). These data suggest that Coll isoforms differentially affect SMC contractile gene expression by altering the formation of SRF-myocardin complexes on the CArG box regions in the promoters of SMC contractile genes.

**Coll IV and Coll I Differentially Regulate Smooth Muscle Cell VCAM-1 Expression**

Although smooth muscle cell phenotypic modulation is classically described as a two-state model whereby cells are in the contractile or synthetic state, it is now clear that there are multiple SMC phenotypes, including an inflammatory phenotype, that depend on the specific gene expression profiles and transcriptomes. VCAM-1 is a cell surface adhesion molecule classically involved in tethering leukocytes to the endothelial cell surface. Although the role of VCAM-1 expression in smooth muscle physiology is unknown, it is postulated to modulate the local inflammatory response within the atherosclerotic plaque. To test whether matrix similarly affected the expression of inflammatory genes, SMCs were plated on either Coll I or Coll IV for 1, 2, or 5 days, and VCAM-1 expression was measured using quantitative RT-PCR and Western blotting. Consistent with Coll I–enhanced phenotypic modulation, SMCs on Coll I displayed a striking increase in both VCAM-1 mRNA (Figure 3A) and protein (Figure 3B) compared to cells plated on Coll IV. The enhanced expression of VCAM-1 in cells on Coll I could be seen by 24 hours both at the mRNA and the protein level, and the differential expression pattern was maintained for at least 5 days.

**Calcineurin/NFAT Signaling Regulates Coll I–Induced Expression of VCAM-1**

To determine the mechanism of matrix-specific VCAM-1 expression, we transfected SMCs with a luciferase construct driven by the VCAM-1 promoter, plated cells on Coll I or Coll IV, and analyzed whether point mutations in the VCAM-1 promoter affected its matrix-specific activation. Interestingly, we found that mutating the binding site for NF-κB, one of the classical regulators of VCAM-1 expression, was sufficient to abolish the matrix-specific effect on VCAM-1 expression (Figure 4). However, no difference could be detected in NF-κB activation between the two matrices by analyzing both nuclear translocation of NF-κB and its phosphorylation state (supplemental Figure I).
The transcription factor NFAT also binds this NF-κB site in the VCAM-1 promoter. Therefore, we used pharmacological inhibitors of both NFAT and NF-κB to determine which transcription factor was required for matrix-specific activation of the VCAM-1 promoter. Treating SMCs plated on Coll I with the NF-κB inhibitor SN50, a cell-permeable inhibitory peptide, had no effect on VCAM-1 expression (Figure 5A), although SN50 was able to reduce interleukin (IL)-1β-induced VCAM-1 expression (supplemental Figure II). NFAT activation requires its dephosphorylation by the calcium-sensitive phosphatase calcineurin. Treating cells with the calcineurin inhibitor Cyclosporine A (CsA) resulted in a profound inhibition of VCAM-1 expression at both the protein (Figure 5A) and mRNA level (Figure 5B). The effect of CsA on VCAM-1 expression was not altered by simultaneous addition of SN50, suggesting that NFAT may be the primary regulator of matrix-specific VCAM-1 expression. In addition, both CsA and the NFATc inhibitor A-285222 block Coll I-induced VCAM-1 promoter activity in the luciferase assay (Figure 5C). To verify that NFAT transcriptional activity was enhanced on Coll I, we transfected SMCs with an NFATc-luciferase reporter construct (3 NFATc cis elements, Clontech) and plated cells on Coll I or Coll IV in the absence or presence of CsA for 6 and 24 hours. Consistent with NFAT-driven VCAM-1 expression, NFAT activity was significantly enhanced on Coll I compared to Coll IV at the 6-hour time point (Figure 5D). CsA treatment abolished the increased luciferase activity seen on Coll I, confirming that the increased luciferase activity is NFATc-dependent.

**Discussion**

The work presented herein describes for the first time a mechanism by which different matrices regulate SMC contractile and inflammatory gene expression. Compared to Coll I, SMCs plated on the normal basement membrane component Coll IV have high levels of SMA and SM-MHC expression, enhanced SRF recruitment to CArG boxes in the SMA and SM-MHC promoters, and increased expression of the SRF coactivator myocardin (Figure 6). In contrast to the contractile genes, cells plated on Coll I have significantly enhanced VCAM-1 expression. Luciferase constructs driven by the VCAM-1 promoter illustrate that mutation of the NF-κB and NFAT-binding sites result in reduced promoter activity. Whereas NF-κB does not show differential activation on the matrices and NF-κB inhibitory peptides do not reduce VCAM-1 expression in cells on Coll I, NFAT transcriptional activity is enhanced in cells on Coll I and blocking NFAT activation significantly reduces Coll I–associated VCAM-1 expression (Figure 6). Although these data do not specifically exclude a role for matrix-specific effects on NF-κB activity, nor identify the specific NFATc isoform (future directions), the differential VCAM-1 expression when NFAT is inhibited but NF-κB activity is not suggests that any differential affects on NF-κB activity are insufficient to produce matrix-specific VCAM-1 expression.

**Collagen and the Regulation of Smooth Muscle–Specific Gene Expression**

SRF regulates both “immediate early” genes and smooth muscle-specific contractile gene expression, the latter of which involves the presence of specific cofactors such as myocardin. During development, myocardin is required and sufficient to induce a smooth muscle–specific gene expression program. In contrast, expression of myocardin in SMCs is decreased during phenotypic modulation in vivo and in response to known regulators of phenotypic modulation in vitro. Regulation of myocardin expression involves an enhancer sequence 35 kb distal to the myocardin promoter containing binding sites for the transcription factors Mef2c, Foxo4, and TEAD. Met2c can be activated by p38, which has been reported to be regulated by collagen in other...
Recently, p38 signaling was shown to be critical for cardiac differentiation through its effects on Mef2c and myocardin.32 However, we could not identify any changes in the p38 activation profile between Coll I and Coll IV (supplemental Figure III). Posttranslational modifications including phosphorylation and acetylation regulate Foxo4 activity,33 whereas phosphatases and deacetylases can inhibit Foxo4. Calcineurin can dephosphorylate and inhibit Foxo4,34 and data presented herein suggest that Coll I enhances calcineurin-NFAT signaling to induce VCAM-1 expression. Therefore, enhanced calcineurin activation on Coll I could mediate its effects on both proinflammatory and smooth muscle-specific genes. Future studies will attempt to identify the transcription factors important for matrix-specific myocardin expression and to identify the molecular mechanisms involved in this regulation (dashed arrows in Figure 6).

**NFAT and VCAM-1 Expression**

While the function of cell cycle regulators and profibrotic genes in atherosclerotic progression are well described, the role of inflammatory gene expression in smooth muscle cells has puzzled scientists for more than a decade.6 Multiple models of atherosclerosis show enhanced SMC expression of VCAM-1 and P-selectin, proteins involved in leukocyte recruitment.35–37 Although the precise role remains unknown, the expression of VCAM-1 in neointimal SMCs may serve to limit the migration of inflammatory cells in the tissue6 or enhance the local activation of T cells.38,39 Surprisingly, recent work using VCAM-1 siRNA demonstrated a requirement for VCAM-1 expression for SMC migration and to a lesser extent proliferation, although the mechanisms behind this regulation are unknown.40 Activation of the proinflammatory transcription factor NF-κB in SMCs results in enhanced expression of matrix metalloproteinases41 and inhibitor of apoptosis protein-1,42 which has profound clinical implications because degradation of the basement membrane and SMC apoptosis are both associated with plaque vulnerability.43,44 Thus, inflammatory gene expression can be used as a marker of smooth muscle phenotypic modulation and may play an important role in the pathology of atherosclerosis. The NF-κB family of transcription factors is a classical proinflammatory signaling pathway, and activation of NF-κB.

**Figure 5.** Coll I promotes NFAT-dependent VCAM-1 expression. A, SMCs were pretreated with SN50 (30 μg/mL), CsA (10 μmol/L), or a combination of the two for 1 hour. Cells were plated onto Coll I–coated dishes in the presence of the inhibitors for 24 hours. VCAM-1 protein expression was determined. A representative image is shown. n = 3, in triplicate, P < 0.01. B, SMCs were transfected with VCAM-1 luciferase constructs. Cells were trypsinized and plated onto Coll I– and Coll IV–coated plates in the presence of CsA or A-285222 (10 μmol/L). Luciferase assays were performed after 6 hours of plating. Biological replicates in triplicate; n = 3, in triplicate, P < 0.05. C, SMCs were transfected with VCAM-1 luciferase constructs. Cells were trypsinized and plated onto Coll I– and Coll IV–coated plates in the presence of CsA or A-285222 (10 μmol/L). Luciferase assays were performed after 6 hours of plating. Biological replicates in triplicate; n = 3, in triplicate, P < 0.05. D, SMCs expressing an NFATc-driven luciferase construct were trypsinized and plated onto Coll I– and Coll IV–coated plates in the presence of CsA or A-285222 (10 μmol/L). Luciferase assays were performed after 6 hours of plating. Biological replicates in triplicate; n = 3, in triplicate, P < 0.05.
is required for VCAM-1 induction in several experimental systems.\textsuperscript{45} For those reasons, it was surprising to see no difference in NF-κB activation between the two matrices and no effect of the NF-κB inhibitor SN50 on Coll I–induced VCAM-1 expression. Although Coll I–induced VCAM-1 expression did require the NF-κB binding sites in the VCAM-1 promoter, these sites can also recruit NFAT to induce VCAM-1 expression.\textsuperscript{27} Although we could not detect reliable enhancement of NFATc1 or c4 binding to the VCAM-1 promoter by ChIP assay (data not shown), NFAT transcriptional activity was increased in SMCs on Coll I, and inhibiting CaN/NFAT signaling with the calcineurin inhibitor CsA or the NFATc inhibitor A-285222 completely blocked VCAM-1 expression in cells on Coll I. Underlining the importance of this region in the VCAM-1 promoter, recent work comparing the atheroprone C57Bl/6J mouse and the atherosensitive C3H mouse demonstrated that C3H mice contain a single nucleotide polymorphism in the NF-κB binding site of the VCAM-1 promoter associated with reduced VCAM-1 expression and diminished atherosclerosis.\textsuperscript{46} Identifying the specific NFATc isoform(s) (1–4) will be paramount to further understanding the role of NFAT in SMC inflammatory gene responses.

Collagen Receptors in Phenotypic Modulation

One potentially interesting aspect of this work is the mechanism by which cells differentiate between Coll I and Coll IV. When denatured, both Coll I and Coll IV can bind to the RGD-binding integrin αvβ3 typically associated with phenotypic modulation.\textsuperscript{47,48} However, interactions with αvβ3 likely do not mediate these matrix-specific effects because the Coll was coated under native conditions and αvβ3 binds both denatured matrices. Both types of native collagen bind to similar integrins, although α1β1 preferentially binds Coll IV and α2β1 preferentially binds to Coll I.\textsuperscript{49} In addition, α1β1 shows strong expression in healthy SMCs, whereas α2β1 shows enhanced expression during phenotypic modulation both in vivo and in vitro.\textsuperscript{50} The role of α2β1-specific signaling in SMC phenotypic modulation is an interesting target for future studies. Another potential mechanism for collagen isotype-specific signaling is differential regulation of the discoidin domain family of receptors, including both DDR1 and DDR2. DDR1 knockout mice have impaired migration on Coll I and show reduced expression of matrix metalloproteinase (MMP)-2 and MMP-9.\textsuperscript{51} Whether differential signaling through these receptors could be mediating the matrix specific effects on smooth muscle phenotype modulation is currently unknown and a future area of investigation (Figure 6). Although the relevance of monomeric Coll I to SMCs in vivo is unclear, monomeric Coll I provides a useful model system to identify the receptors and signaling mechanisms that mediate Coll-induced changes in SMC phenotype. The current work shows for the first time a molecular mechanism for differential SMC contractile and inflammatory gene expression in response to protective basement membrane Coll IV and atherosclerotic monomeric Coll I (Figure 6). These data underscore the importance of the matrix in smooth muscle physiology and identify novel levels of regulation by the SMC matrix. Phenotypic modulation of SMCs is known to play an important role in atherosclerotic progression, with SMCs contributing to the clinical outcome of this pathological vessel remodeling. Furthermore, SMCs play a major role in neointimal formation in balloon-induced injury from angioplasty, in vein grafts, and in response to vascular stents. Through better understanding of how SMCs sense the protective versus atherosclerotic matrices, we hope to identify novel therapeutic approaches to limit SMC phenotypic modulation and to improve the design of vascular stents to limit pathological SMC growth.

Acknowledgments

We thank Patrick Albert for assistance with quantitative RT-PCR, Sean Garvey for assistance with the inhibitor experiments, and William Aird (Harvard Medical School, Boston, Mass) and Takashi Minami (The University of Tokyo) for the generous gift of the VCAM-1 luciferase constructs.

Disclosures

None.

References


Molecular Mechanisms of Collagen Isotype-Specific Modulation of Smooth Muscle Cell Phenotype
A. Wayne Orr, Monica Y. Lee, Julia A. Lemmon, Arif Yurdagul, Jr, Maria F. Gomez, Pamela D. Schoppee Bortz and Brian R. Wamhoff

Arterioscler Thromb Vasc Biol. 2009;29:225-231; originally published online November 20, 2008;
doi: 10.1161/ATVBAHA.108.178749

Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/29/2/225

Data Supplement (unedited) at:
http://atvb.ahajournals.org/content/suppl/2009/01/26/ATVBAHA.108.178749.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org//subscriptions/
Figure S1  “Supplemental Material”

A.  

<table>
<thead>
<tr>
<th>Coll:</th>
<th>24 h</th>
<th>48 h</th>
<th>5 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

VCAM  
P-p65  
ERK  

p65 phosphorylation (fold)

Coll: I I IV I IV I IV

B.  

Collagen I  
Collagen IV  

2 h  6 h  12 h  1 day  2 day  5 day  2 h  6 h  12 h  1 day  2 day  5 day
Figure S2  

“Supplemental Material”

![Graph showing the fold change in VCAM-1 protein levels with different treatments.](image-url)

- **IL-1β** and **SN50** treatments indicated.
- **p < 0.001** and **p < 0.01** annotations signify statistical significance.

**Y-axis:** VCAM-1 protein (fold)

**X-axis:** Treatments:
- IL-1β
- SN50
Figure S3

"Supplemental Material"

- **Coll**: I & IV
- **24 h**: I & IV
- **48 h**: I & IV
- **5 days**: I & IV

**P-p38**

**ERK**

**p38 phosphorylation (fold)**

24 hr

48 hr

5 days

--

Coll: I & IV

---

Coll: I & IV

---

Coll: I & IV

---
MATERIALS AND METHODS

Cell culture and reagents. Primary rat aortic SMCs grown in a 50:50 mixture of DMEM and F12 media supplemented with 10% fetal bovine serum and the antibiotics penicillin and streptomycin. Cells were growth arrested at confluency for 3 days to induce the expression of smooth muscle contractile genes and promote a differentiated phenotype. To test for the effect of matrix composition, cell culture plates were coated with Coll I (20 μg/ml; Sigma) or Coll IV (20 μg/ml; Chemicon and Trevigen) overnight at 4°C. Plates were then washed with serum free media, and rat aortic SMCs were plated in serum free media at near confluence (3 x 10^4 cells/cm^2) for the indicated time depending upon the experimental readout. In some experiments, the inhibitors SN50 (Axxora, 30 μg/ml), cyclosporine A (Sigma, 10 μM), or A-285222 (a gift from Abbott Pharmaceuticals, 10 μM) were given for 1 hour prior to experiment initiation to inhibit NF-κB and NFAT signaling, respectively.

Luciferase Assays. SMCs were transfected (FuGene 6) with promoter-reporter (luciferase) constructs at 70% confluency containing the smooth muscle myosin heavy chain promoter (SMMHC-luc), SM alpha actin promoter (SMαA-luc), VCAM-1 promoter (VCAM-1-luc), VCAM-1 promoter with a mutated NFkB/NFAT site (mutVCAM-1-luc), NFATc binding elements (NFATc-luc, Conetech), or SMα promoter containing point mutations in the CArG A, CArG B, or intronic CArG sequence. SMCs were grown to confluency on plastic and then growth arrested for 24-36 hrs. SMCs were then trypsinized and replated onto Coll I or Coll IV for the denoted time and luciferase assay performed.

Quantitative RT-PCR. Total RNA was extracted with TRIzol reagent (Invitrogen), and cDNAs were produced with the BioRad iScript cDNA Synthesis kit per manufacturer’s instructions. To quantify the mRNA, real-time PCR was performed using a BioRad iCycler and the Sybr green visualization dye. All results were normalized to 18S and are expressed as a ratio of target mRNA to 18S mRNA.

Western blotting. Cell lysis and immunoblotting were performed to measure protein expression and posttranslational modification. Briefly, cells were lysed directly in SDS Sample buffer, separated by SDS-PAGE gels, and transferred to a PVDF membrane. The membrane were analyzed by western blotting with mouse anti-SMα-actin (Sigma; 1:5000), goat anti-VCAM (Santa Cruz Biotechnology, 1:500), and rabbit anti-ERK (Santa Cruz Biotechnology; 1:5000). Resulting bands were scanned to tiff files, and band intensity was determined using ImageJ.

Chromatin Immunoprecipitation. Real-time PCR was performed on 1 ng genomic DNA from ChIP. Real-time PCR primers were designed to flank the 5′-CArG elements of SMα-actin and SMMHC, the c-fos CArG. Quantification of protein:DNA interaction/enrichment was determined by the following 2^{Ct(Ref)-Ct(IP)} -2^{Ct(Ref)-Ct(No antibody control)}. 
Primer sequences were as follows: *SM α-actin* 5-agcagaacagagaatgcagtggaagac-3, 5-cctcccactgcctcccaaaggagc-3; *SMMHC* 5.-ctgcgcgggaccatatggtagggag3, 5-cctggegggagaccaaaaaagggcagg-3
SUPPLEMENTAL DATA

Figure S1. NF-κB localization and phosphorylation are not differentially regulated by Coll I and Coll IV. (A) SMC plating times on Coll I or Coll IV were varied at 24h, 48h, or 5 days, and phosphorylation of the NF-κB p65 subunit was determined using a phosphorylation site-specific antibody. A representative image is shown. n = 3. (B) SMC plating times on Coll I or Coll IV were varied at 2h, 6h, 12h, 24h, 48h, or 5 days. Cells were fixed in formaldehyde and nuclear translocation of the NF-κB p65 subunit was determined by immunocytochemistry. Representative images are shown. n = 3.

Figure S2. SN50 reduces IL-1β-induced VCAM-1 expression. SMCs were plated onto Coll IV and some cells were treated with the NF-κB inhibitor SN50 for 1 hour. Cells were then treated for 24 hours with IL-1β (5 μg/ml). VCAM-1 expression was assessed by Western Blotting as previously described. n = 3 duplicate experiments. * p < 0.001.

Figure S3. Coll I and Coll IV do not differentially regulate p38. SMC plating times on Coll I or Coll IV were varied at 24h, 48h, or 5 days, and phosphorylation of p38 was determined using a phosphorylation site-specific antibody. A representative image is shown. n = 3.